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Summary
Background.  —  Osteoprotegerin  plays  a  critical  role  in  the  pathogenesis  of  atherosclerosis.  Ele-
vated osteoprotegerin  concentrations  have  been  reported  in  microvascular  complications  of
diabetes. Patients  with  diabetes  are  at  increased  risk  of  macrovascular  complications,  partic-
ularly peripheral  artery  disease  (PAD).
Aim.  —  To  investigate  the  association  between  osteoprotegerin  concentration  and  PAD  in  dia-
betes.
Methods.  —  In  a  cross-sectional  setting,  patients  with  type  2  diabetes  for  >  5  years  and  no  appar-Ankle-brachial  index ent diabetic  foot  ulcer  were  recruited.  Patients  underwent  colour  Doppler  ultrasonography  of
lower limbs  and  were  designated  PAD+  if  arterial  narrowing  was  detected.  Ankle-brachial  index
(ABI) was  measured.  Serum  osteoprotegerin  concentrations  were  determined.
Results.  —  Ninety-eight  patients  (47  PAD+,  51  PAD—)  were  recruited.  Osteoprotegerin  concen-
trations (median  [interquartile  range])  were  signiﬁcantly  higher  in  PAD+  versus  PAD—  patients
Abbreviations: ABI, ankle-brachial index; BMI, Body Mass Index; HbA1c, glycated haemoglobin A1c; HDL-C, high-density lipoprotein
holesterol; hsCRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PSV, peak
ystolic velocity; RANKL, receptor activator of nuclear factor kappa-B ligand.
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(0.80  [0.50—1.95]  ng/mL  vs  0.30  [0.25—0.40]  ng/mL;  P  <  0.001).  In  logistic  regression,  log-
osteoprotegerin  was  a  predictor  of  PAD  in  univariate  and  multivariable  analyses.  In  the  ﬁnal
multivariable  model,  adjusting  for  age,  sex,  body  mass  index,  smoking,  hypertension,  glycaemic
control, lipid  proﬁle,  renal  function  and  C-reactive  protein,  one  standard  deviation  increase  in
log-osteoprotegerin  was  associated  with  a  more  than  twofold  increase  in  the  risk  of  having  PAD
(odds ratio  2.26,  95%  conﬁdence  interval  1.50—3.40).  In  PAD+  patients,  osteoprotegerin  was  a
signiﬁcant  predictor  of  disease  severity,  determined  by  ABI  and  percentage  of  vessel  occlusion
in univariate  and  multivariable  models.
Conclusions.  —  Osteoprotegerin  concentrations  are  increased  in  patients  with  diabetes  and  PAD.
Osteoprotegerin  is  an  independent  predictor  of  the  presence  and  severity  of  PAD  in  diabetic
patients.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  L’ostéoprotégérine  joue  un  rôle  critique  dans  la  pathogénie  de  l’athérosclérose.
Des concentrations  élevées  d’ostéoprotégérine  sont  associées  aux  complications  microvas-
culaires  du  diabète.  Les  patients  diabétiques  sont  à  risque  accru  de  complications
macrovasculaires  en  particulier  d’artériopathie  oblitérante  des  membres  inférieurs  (AOMI).
Objectif.  —  Évaluer  l’association  entre  les  concentrations  d’ostéoprotégérine  et  l’artériopathie
oblitérante  des  membres  inférieurs  chez  les  patients  diabétiques.
Méthode.  —  Cette  étude  transversale  a  inclus  des  patients  ayant  un  diabète  de  type  2  datant
de plus  de  5  ans  et  pas  de  pied  diabétique.  Les  patients  ont  eu  une  échographie  Doppler  des
membres  inférieurs  et  ont  été  caractérisés  comme  ayant  une  artériopathie  oblitérante  des
membres  inférieurs  en  présence  d’une  sténose  artérielle.  L’index  de  pression  systolique  a  été
mesuré. Les  concentrations  d’ostéoprotégérine  ont  été  déterminées.
Résultats.  —  Quatre-vingt-dix-huit  patients  (47  AOMI+,  51  AOMI—)  ont  été  inclus.  Les  concentra-
tions d’ostéoprotégérine  (valeur  médiane,  interquartile  range)  ont  été  signiﬁcativement  plus
élevées chez  les  patients  à  AOMI+  versus  les  patients  AOMI—  (0,80  (0,50—1,95)  ng/mL  versus
0,30 (0,25—0,40)  ng/mL,  p  <  0,001).  En  régression  logistique,  le  log  ostéoprotégérine  était  un
prédicteur  de  l’AOMI  en  analyses  univariée  et  multivariée.  Dans  le  modèle  d’analyse  multivariée
ﬁnal, ajusté  sur  l’âge,  le  sexe,  l’indice  de  masse  corporelle,  le  tabac,  l’hypertension  artérielle,
le contrôle  glycémique,  le  proﬁl  lipidique,  la  fonction  rénale  et  la  CRP,  une  augmentation  d’une
déviation  standard  de  la  valeur  log-ostéoprotégérine  est  associée  avec  une  augmentation  d’au
moins deux  fois  le  risque  de  présenter  une  AOMI  (odds  ratio  2,26),  IC  95  %  1,50—3,40).  Chez
les patients  AOMI+,  l’ostéoprotégérine  est  un  prédicteur  signiﬁcatif  de  la  sévérité  de  la  mal-
adie artérielle  périphérique  déterminée  par  l’index  de  pression  systolique  et  la  sévérité  de
l’occlusion  artérielle  en  analyse  univariée  et  mutivariée.
Conclusion.  —  Les  concentrations  d’ostéoprotégérine  sont  augmentées  chez  les  patients  diabé-
tiques ayant  une  AOMI.  L’ostéoprotégérine  est  un  prédicteur  indépendant  de  la  présence  et  de
la sévérité  d’une  AOMI  chez  les  patients  diabétiques.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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to  more  amputations  and  a  higher  risk  of  mortality  [7].Background
Peripheral  artery  disease  (PAD)  is  characterized  by  gradual
and  progressive  narrowing  and  subsequent  occlusion  of  the
arteries  of  the  lower  extremities  secondary  to  atherosclero-
sis  [1,2].  Potentially  life-threatening  in  cases  with  complete
vessel  blockade,  PAD  is  associated  with  signiﬁcant  pain,  loss
of  function  and  disability  [3—5].  Given  the  shared  cause,
patients  with  PAD  are  also  at  increased  risk  of  cardiovascular
and  cerebrovascular  diseases  [5].
PAD  is  a  major  risk  factor  for  lower-extremity  ampu-
tation,  especially  in  patients  with  diabetes  [4].  Indeed,
m
fiabetes  carries  an  additional  risk  for  having  PAD  [4—7].
etermining  the  exact  prevalence  of  PAD  in  patients  with
iabetes  has  been  difﬁcult,  but  available  estimates  suggest
hat  about  10.8%  of  diabetic  patients  have  PAD,  roughly
hree  times  as  many  as  non-diabetic  individuals  [2].  If  a
atient  is  diagnosed  with  PAD,  there  is  a  26.4%  chance  of
iabetes  being  present  [2].  Furthermore,  in  patients  with
iabetes,  PAD  assumes  a  more  notorious  trajectory,  leadingOsteoprotegerin,  a  secretory  basic  glycoprotein,  is  a
ember  of  the  tumour  necrosis  factor  receptor  super-
amily  and  acts  as  an  inhibitor  of  bone  resorption  [8].
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immunosorbent  assay  method.  Serum  calcium  and  phos-
phorus  concentrations  were  measured  with  an  autoanalyser14  
steoprotegerin  is  produced  by  various  organs  and  tissues,
uch  as  the  lungs,  intestines,  kidneys,  bones  and  the
ardiovascular  system  (heart,  arteries  and  veins),  and
lso  by  haematopoietic  and  immune  cells  [8];  it  acts  as
n  important  regulatory  molecule  in  the  vasculature  [9].
steoprotegerin-deﬁcient  mice  develop  severe  osteoporosis
nd  calciﬁcation  of  the  aorta  and  renal  artery.  Interestingly,
he  process  follows  a  pattern  similar  to  that  of  the  medial
alciﬁcation  commonly  seen  in  vascular  complications  of
iabetes  [10].  Serum  osteoprotegerin  concentrations  are
ssociated  with  the  severity  of  coronary  artery  stenosis,
nd  a  modest  correlation  is  also  found  with  the  number  of
nvolved  vessels  [11,12].  Moreover,  Ziegler  et  al.  reported
 positive  correlation  between  serum  concentrations  of
steoprotegerin  and  severity  of  PAD  [13].
Previous  studies  have  shown  that  plasma  concentra-
ions  of  osteoprotegerin  are  increased  in  diabetic  versus
on-diabetic  individuals  [14—17].  Elevated  concentrations
f  osteoprotegerin  have  also  been  reported  in  diabetic
atients  with  non-proliferative  retinopathy  or  microalbu-
inuria  [16].  Despite  a  conﬁrmed  role  for  osteoprotegerin
n  macro-  and  microvascular  complications  of  diabetes,  the
ossibility  of  a  link  between  osteoprotegerin  and  PAD  in
atients  with  diabetes  has  received  little  attention.  There-
ore,  the  present  study  was  designed  to  investigate  whether
erum  osteoprotegerin  concentrations  are  associated  with
AD  in  patients  with  type  2  diabetes.
ethods
atients
n  the  present  cross-sectional  study,  consecutive  patients
ith  type  2  diabetes  who  visited  the  outpatient  diabetes
linic  of  Vali-Asr  Hospital  (a  teaching  hospital  afﬁliated  with
ehran  University  of  Medical  Sciences,  Tehran,  Iran)  from
arch  2012  to  March  2013,  were  assessed  and,  if  eligible,
ere  enrolled.  Patients  were  included  if  they  had  had  type  2
iabetes  for  >  5  years  and  agreed  to  undergo  colour  Doppler
ltrasonographic  evaluation  of  the  lower  extremities.
iabetes  was  diagnosed  according  to  the  criteria  delineated
y  the  American  Diabetes  Association  [18].  As  the  diag-
osis  had  been  made  at  least  5  years  earlier,  the  recently
nnexed  HbA1c criterion  was  not  employed.  Patients  were
ot  included  if  they  were  diagnosed  with  chronic  diseases
f  the  liver,  lungs  or  kidneys,  or  if  they  had  had  a  recent
cute  infection.  Patients  were  also  ineligible  if  they  were
aking  vitamin  D,  calcium  supplements,  bisphosphonates  or
orticosteroids.  A  complete  medical  history  was  obtained
nd  a  thorough  physical  examination  performed.  Patients
ere  then  sent  for  ultrasonographic  evaluation  of  the  lower
xtremities  in  the  hospital’s  radiology  department.  Written
nformed  consent  was  obtained  from  all  participants.  All
rocedures  dealing  with  human  subjects  were  conducted
n  accordance  with  the  latest  revision  of  the  Declaration
f  Helsinki.  The  ethics  committee  of  the  hospital  approved
he  study  protocol.ssessments
hysical  examination  included  the  measurement  of  height
nd  weight  and  determination  of  ankle-brachial  index  (ABI).
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eight  was  measured  with  the  patient  standing  erect  in  front
f  a  standard  stadiometer  and  was  recorded  to  the  nearest
.1  cm.  Weight  was  measured  with  subjects  wearing  only
ight  clothing,  using  a  calibrated  scale,  and  was  recorded
o  the  nearest  0.1  kg.  Body  mass  index  (BMI)  was  calcu-
ated  as  weight  divided  by  height  squared  (kg/m2).  ABI  was
easured  with  patient  lying  in  the  supine  position.  After
t  least  10  minutes  of  resting,  brachial  systolic  blood  pres-
ure  was  measured  with  an  appropriately  sized  cuff  and  a
oppler  ultrasonographic  probe  being  placed  in  the  ante-
ubital  fossa.  Systolic  blood  pressure  was  measured  from
oth  arms  and  the  higher  of  the  two  readings  was  designated
s  brachial  pressure.  An  appropriately  sized  cuff  was  then
laced  around  the  leg  between  malleolus  and  the  calf.  Using
 similar  technique,  systolic  blood  pressure  was  measured
y  placing  the  probe  on  the  anterior  tibialis  and  dorsalis
edis  arteries,  and  the  point  of  signal  reappearance  when
eﬂating  the  cuff  was  recorded.  The  higher  of  the  two  mea-
urements  was  then  regarded  as  the  ankle  pressure.  Finally,
BI  was  calculated  by  dividing  ankle  by  brachial  systolic
ressures.
All  ultrasonographic  evaluations  were  performed  by  a  sin-
le  experienced  radiologist.  Colour  Doppler  ultrasonography
as  used  to  detect  PAD  and  its  severity.  Peak  systolic  veloc-
ty  (PSV)  was  determined  by  using  a  7  MHz  convex  transducer
SonoScape,  Shenzhen,  China)  in  each  arterial  segment.  The
SV  ratio  was  then  deﬁned  as  the  ratio  of  the  PSV  at  the  site
f  measurement  divided  by  the  PSV  in  the  proximal  (approx-
mately  4  cm)  artery.  A  PSV  ratio  of  2.4  was  used  to  deﬁne
igniﬁcant  stenosis,  corresponding  to  >  50%  narrowing  in  the
iameter  of  the  arterial  lumen.  For  severity  of  stenosis,
eference  PSV  ratio  values  developed  by  Ranke  et  al.  [19]
ere  used.  Based  on  their  report,  PSV  ratio  values  of  ≥2.9,
3.4,  ≥4.7  and  ≥7.0  correlated  with  ≥60%,  ≥70%,  ≥80%
nd  ≥90%  stenosis,  respectively,  in  angiographic  assessment
19].
aboratory evaluations
ntecubital  venous  blood  samples  were  collected  after  at
east  12  hours  of  fasting.  Serum  concentrations  of  fast-
ng  plasma  glucose  were  determined  using  the  glucose
xidase  method.  Percentage  of  glycated  haemoglobin  A1c
HbA1c) was  determined  using  the  high  performance  liq-
id  chromatography  method.  The  lipid  proﬁles  of  patients,
ncluding  total  cholesterol,  low-density  lipoprotein  choles-
erol  (LDL-C),  high-density  lipoprotein  cholesterol  (HDL-C)
nd  triglycerides,  were  determined  using  enzymatic  meth-
ds  (ParsAzmun,  Karaj,  Iran).  The  Jaffe  method  was
mployed  to  assess  serum  concentrations  of  creatinine
ParsAzmun,  Karaj,  Iran).  In  PAD+  patients,  high  sen-
itivity  C-reactive  protein  (hsCRP)  concentrations  were
ssessed  with  commercial  kits  (Diagnostics  Biochem  Canada
nc.,  Dorchester,  ON,  Canada),  using  the  enzyme-linkedHitachi  704,  Tokyo,  Japan).  Serum  osteoprotegerin  concen-
rations  were  determined  using  a  human  osteoprotegerin
nzyme-linked  immunosorbent  assay  kit  (Cusabio,  Wuhan,
hina).
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Statistical analysis
Data  were  analysed  using  SPSS  version  16  for  Windows  (SPSS
Inc.,  Chicago,  IL,  USA).  Continuous  variables  with  normal
distribution  are  presented  as  means  ±  standard  deviations
and  categorical  variables  are  presented  as  proportions.
Baseline  characteristics  of  patients  with  and  without  PAD
were  compared  using  an  independent  t test  or  the  chi-
square  test.  Initially,  given  the  non-normal  distribution  and
right-sided  skewness,  osteoprotegerin  concentrations  were
presented  as  medians  (25th—75th  percentiles)  and  were
compared  between  patients  with  and  without  PAD  using
the  Mann-Whitney  U  test.  For  all  subsequent  paramet-
ric  analyses,  a  logarithmic  transformation  was  done  and
log-osteoprotegerin  was  used  instead.  To  assess  the  asso-
ciation  between  log-osteoprotegerin  and  the  presence  of
PAD,  univariate  and  multivariable  logistic  regression  models
were  constructed.  Odds  ratios  and  95%  conﬁdence  intervals
were  calculated  in  each  model  per  one  standard  devi-
ation  increase  in  log-osteoprotegerin.  To  investigate  the
association  between  osteoprotegerin  and  PAD  severity,  lin-
ear  regression  was  used  in  the  subset  of  PAD+  patients.
In  univariate  and  multivariable  regression  models,  ABI  (or
the  percentage  of  arterial  occlusion)  served  as  the  depen-
dent  variable  and  the  standardized  beta  coefﬁcient  for
log-osteoprotegerin  was  calculated.  In  all  tests,  the  null
hypothesis  was  rejected  where  P  was  <  0.05.
Results
A  total  of  98  patients  (51  PAD—,  47  PAD+)  were  included
in  the  analysis.  Baseline  characteristics  of  enrolled  patients
are  presented  in  Table  1,  according  to  PAD  group.  The  aver-
age  age  of  the  participants  was  64  years  (range,  36—89
years)  and  was  not  different  between  the  two  groups.
Patients  in  the  PAD—group  were  more  likely  to  be  female
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Table  1  Baseline  characteristics  of  study  participants  (diabet
PAD− (n  =  51)  
Women/men  (n/n)  33/18  
Age  (years)  63.43  ±  10.91  
BMI  (kg/m2)  28.27  ±  4.91  
Hypertension  23  (45.1)  
Cigarette  smoking  7  (13.7)  
Duration  of  diabetes  (years)  12.41  ±  7.06  
Family  history  of  PAD  2  (3.9)  
HbA1c  (%)  8.61  ±  1.71  
Triglycerides  (mg/dL)  1.82  ±  0.70  
Total  cholesterol  (mg/dL)  4.51  ±  0.94  
HDL-C  (mg/dL)  1.04  ±  0.20  
LDL-C  (mg/dL) 2.64  ±  0.83  
Creatinine  (mg/dL)  79.3  ±  16.01  
Calcium  (mg/dL) 2.23  ±  0.18  
Phosphorus  (mg/dL) 1.23  ±  0.14
Data are expressed as mean ± standard deviation or number (%), unle
sedimentation rate; HOMA-IR: homeostasis model assessment of insulin
low-density lipoprotein cholesterol; PAD: peripheral artery disease.415
65%  vs  45%);  however,  the  difference  did  not  reach  statisti-
al  signiﬁcance.  Mean  BMI  was  also  similar  in  the  two  groups.
atients  with  PAD  were  more  likely  to  have  hypertension  and
lso  to  have  a positive  history  of  PAD  in  their  ﬁrst-degree
elatives;  in  both  cases  the  difference  was  not  statistically
igniﬁcant.  Patients  were  diagnosed  with  type  2  diabetes
or  a  minimum  and  maximum  of  5  and  30  years,  respec-
ively.  Duration  of  diabetes  was  similar  in  the  two  groups.
igniﬁcantly  better  glycaemic  control  was  achieved  in  PAD—
atients;  on  average,  their  HbA1c values  were  0.9%  lower
han  in  those  with  PAD  (P  =  0.016).  A  worse  lipid  proﬁle  was
bserved  in  PAD+  patients;  they  had  higher  concentrations
f  serum  triglycerides,  total  cholesterol  and  LDL-C,  but  not
DL-C  (Table  1).  No  patient  had  a  serum  creatinine  concen-
ration  >  1.4  mg/dL.  On  average,  patients  in  the  PAD+  group
ad  higher  serum  creatinine  concentrations  (P  =  0.046).  Cal-
ium  and  phosphorus  concentrations  were  similar  in  the
wo  groups.  Osteoprotegerin  concentrations  were  signiﬁcan-
ly  higher  in  PAD+  versus  PAD—  patients  (0.80  [0.50—1.95]
g/mL  vs  0.30  [0.25—0.40]  ng/mL;  P  <  0.001).  Osteoprote-
erin  concentrations  were  similar  in  women  and  men  (0.40
0.30—0.73]  ng/mL  in  women  and  0.50  [0.30—0.80]  ng/mL
n  men;  P  =  0.60).
Results  of  binary  logistic  regression  models  for  the  asso-
iation  of  log-osteoprotegerin  with  the  presence  of  PAD
n  patients  with  diabetes  are  depicted  in  Table  2.  In  the
nivariate  model,  each  standard  deviation  increment  in  log-
steoprotegerin  was  associated  with  a  twofold  increase  in
he  chance  of  having  PAD  on  colour  Doppler  US.  After  con-
rolling  for  the  effects  of  multiple  confounding  variables,
ncluding  age,  sex,  BMI,  hypertension,  cigarette  smoking,
bA1c,  triglycerides,  HDL-C,  total  cholesterol,  creatinine,
alcium  and  phosphorus,  the  observed  relationship  retained
ts  signiﬁcance,  indicating  that  log-osteoprotegerin  is  an
ndependent  predictor  of  PAD  irrespective  of  various  demo-
raphic,  clinical  and  laboratory  variables.  In  the  ﬁnal
ultivariable  model,  for  one  standard  deviation  increase
ic  patients  with  and  without  peripheral  artery  disease).
PAD+  (n  =  47)  P
21/26  0.07
64.74  ±  9.38  0.53
29.43  ±  5.04  0.26
30  (63.8)  0.07
13  (27.7)  0.16
13.62  ±  5.91  0.36
7  (14.9)  0.08
9.52  ±  1.96  0.016
2.13  ±  0.76  0.040
5.17  ±  33.56  0.001
1.03  ±  0.25  0.86
3.22  ±  0.68  <0.001
85.41  ±  12.96  0.046
2.25  ±  0.26  0.65
1.29  ±  0.20  0.07
ss otherwise indicated. BMI: body mass index; ESR: erythrocyte
 resistance; HDL-C: high-density lipoprotein cholesterol; LDL-C:
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Table  2  Logistic  regression  models  for  association  of  osteoprotegerin  with  peripheral  artery  disease.
ORa (95%  CI)  P
Baseline  modelb 2.00  (1.50—2.66)  <0.001
Adjusted  for  age  and  sex  2.04  (1.51—2.75)  <0.001
Adjusted  for  age,  sex  and  BMI  2.03  (1.51—2.74)  <0.001
Adjusted  for  age,  sex,  BMI,  hypertension  and  cigarette  smoking  2.05  (1.51—2.79)  <0.001
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration
of  diabetes  and  HbA1c
2.06 (1.50—2.83)  <0.001
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration
of  diabetes,  HbA1c,  triglycerides,  HDL-C  and  total  cholesterol
1.99  (1.43—2.75) <0.001
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration
of  diabetes,  HbA1c,  triglycerides,  HDL-C,  total  cholesterol,
creatinine,  calcium  and  phosphorus
2.26 (1.50—3.40)  <0.001
BMI: body mass index; CI: conﬁdence interval; HbA1c: glycated haemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; OR: odds
ratio.
a OR calculated per one standard deviation increase in log-osteoprotegerin.
b Log-transformed osteoprotegerin as the independent variable.
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An  log-osteoprotegerin,  the  risk  of  having  PAD  rose  by  226%
odds  ratio  2.26,  95%  conﬁdence  interval  1.50—3.40).
The  group  of  patients  with  PAD  was  further  analysed
o  investigate  whether  log-osteoprotegerin  is  a  signiﬁcant
redictor  of  PAD  severity;  the  ﬁndings  are  summarized
n  Table  3.  Log-osteoprotegerin  values  were  signiﬁcantly
nd  negatively  associated  with  ABI  in  the  univariate  linear
egression  model.  After  controlling  for  the  effects  of  the
onfounders  mentioned  above  plus  hsCRP,  the  relationship
ersisted  (standardized  beta  for  the  ﬁnal  model  =  —0.407;
 =  0.045).  On  the  other  hand,  log-osteoprotegerin  was
igniﬁcantly  and  positively  associated  with  degree  of  ves-
el  occlusion  on  Doppler  ultrasonography;  the  higher  the
og-osteoprotegerin  value,  the  more  obstructed  the  artery
standardized  beta  for  univariate  model  =  0.306;  P  =  0.037).
his  observation  was  replicated  in  multivariable  linear
egression  models  as  well,  suggesting  that  the  associa-
ion  between  log-osteoprotegerin  and  arterial  occlusion  is
ndependent  of  age,  sex,  hypertension,  cigarette  smoking,
iabetes  duration,  glycaemic  control,  lipid  proﬁle,  renal
unction  or  inﬂammation  (Table  3).
iscussion
n  the  present  study,  we  demonstrated  that  serum  concen-
rations  of  osteoprotegerin  are  signiﬁcantly  elevated  in  type
 diabetes  patients  with  versus  without  PAD.  Moreover,  in
AD+  patients,  osteoprotegerin  was  a  signiﬁcant  predictor
f  disease  severity,  as  measured  by  ABI  and  percentage  of
rterial  occlusion  on  colour  Doppler  ultrasonography.  The
elationship  retained  its  signiﬁcance  after  adjustment  for
otential  confounding  variables,  suggesting  that  the  rela-
ionship  is  not  dependent  on  or  mediated  by  age,  sex,
MI,  smoking  status,  hypertension,  glycaemic  control,  serum
ipid  proﬁle,  renal  function  and  chronic  inﬂammation.Previous  reports  have  postulated  that  serum  osteo-
rotegerin  might  be  an  independent  risk  factor  for  the
evelopment  and  progression  of  atherosclerosis  in  coronary
rteries  [20].  In  a  sample  of  201  patients  with  stable  angina
p
l
t
mndergoing  coronary  angiography,  Jono  et  al.  demonstrated
hat  serum  osteoprotegerin  concentrations  are  elevated
n  patients  with  coronary  artery  disease  compared  with
hose  in  patients  with  no  stenosis.  Moreover,  in  the  sub-
et  of  diseased  individuals,  osteoprotegerin  concentrations
ncreased  progressively  when  moving  from  single-vessel  to
hree-vessel  disease  [11].  Similar  results  have  also  been
eplicated  in  a  population  of  patients  with  type  2  dia-
etes  with  no  known  coronary  artery  disease  [21].  In  2005,
iegler  et  al.  [13], in  a  study  of  67  patients  with  advanced
AD  of  the  lower  extremities,  showed  a  strong  relation-
hip  between  serum  osteoprotegerin  concentrations  and
AD  severity.  More  recently,  Ali  et  al.  (2009)  lent  further
redence  to  the  discourse  by  showing  that  serum  osteo-
rotegerin  concentrations  are  an  independent  predictor  of
AD  (deﬁned  as  ABI  <  0.9)  in  large  populations  of  African-
mericans  and  non-Hispanic  whites  [22]. In  the  present
eport,  we  extended  previous  research  by  demonstrating
hat  osteoprotegerin  concentrations  are  also  elevated  in  a
opulation  of  PAD  patients  with  type  2  diabetes.
Elevated  concentrations  of  osteoprotegerin  in  the
era  of  diabetic  patients  with  micro-  and  macrovascular
omplications  suggest  that  osteoprotegerin  may  indeed  be
nvolved  in  the  pathogenesis  of  endothelial  dysfunction  and
ascular  damage  [16].  The  precise  mechanisms  by  which
steoprotegerin  advances  atherogenesis  remain  speculative
or  the  most  part;  however,  few  compelling  hypotheses  have
een  formed.
A  key  step  in  the  pathogenesis  of  atherosclerosis  is
ncreased  binding  of  monocytes  to  adhesion  molecules  on
ndothelial  cells  [23].  An  in  vitro  assay  by  Mangan  et  al.
24]  indicated  that  when  human  endothelial  cells  were
ncubated  with  osteoprotegerin,  a  dose-dependent  increase
n  the  expression  of  intercellular  adhesion  molecule-1,
ascular  cell  adhesion  molecule-1  and  E-selectin  ensued.
s  a  result,  endothelial  cells  are  more  sensitized  to  the
roinﬂammatory  effects  of  tumour  necrosis  factor  alpha,
eading  to  an  enhanced  capacity  for  monocyte  binding
o  endothelial  cells  [24]. Furthermore,  osteoprotegerin
ay  also  be  involved  in  the  calciﬁcation  process  of  the
Osteoprotegerin  and  peripheral  artery  disease  417
Table  3  Linear  regression  models  for  association  of  osteoprotegerin  with  severity  of  peripheral  artery  disease.
Standardized  beta  P
Ankle-brachial  index
Baseline  modela —0.345  0.018
Adjusted  for  age  and  sex  —0.344  0.020
Adjusted  for  age,  sex  and  BMI  —0.373  0.014
Adjusted  for  age,  sex,  BMI,  hypertension  and  cigarette  smoking  —0.473  0.003
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration  of
diabetes  and  HbA1c
—0.441 0.010
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration  of
diabetes,  HbA1c,  triglycerides,  HDL-C  and  total  cholesterol
—0.380  0.048
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration  of
diabetes,  HbA1c,  triglycerides,  HDL-C,  total  cholesterol,  creatinine,
hsCRP,  calcium  and  phosphorus
—0.407 0.045
Percentage  of  vessel  occlusion  determined  colour  Doppler  ultrasonography
Baseline  model  0.306  0.037
Adjusted  for  age  and  sex  0.306  0.030
Adjusted  for  age,  sex  and  BMI  0.325  0.025
Adjusted  for  age,  sex,  BMI,  hypertension  and  cigarette  smoking  0.375  0.017
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration  of
diabetes  and  HbA1c
0.308 0.039
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration  of
diabetes,  HbA1c,  triglycerides,  HDL-C  and  total  cholesterol
0.415  0.022
Adjusted  for  age,  sex,  BMI,  hypertension,  cigarette  smoking,  duration  of
diabetes,  HbA1c,  triglycerides,  HDL-C,  total  cholesterol,  creatinine,
hsCRP,  calcium  and  phosphorus
0.410 0.031
BMI: body mass index; HbA1c: glycated haemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; hsCRP: high sensitivity C-reactive
protein.
a Log-transformed osteoprotegerin as the independent variable.
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mvascular  cells  undergoing  apoptosis.  Enhanced  expression  of
osteoprotegerin  has  been  detected  in  the  proximity  of  cal-
ciﬁed  neointimal  lesions  [25].  Of  note,  however,  a  parallel
conjecture  can  also  be  considered.  Increased  osteoprote-
gerin  expression  might  be  a  counter-regulatory  mechanism
aimed  at  negating  the  calciﬁcation  process  of  the  arteries
[25,26].  Although  intravenous  infusion  of  recombinant
osteoprotegerin  and  transgenic  overexpression  of  osteopro-
tegerin  in  homozygote  osteoprotegerin-deﬁcient  mice  do
not  diminish  the  already-present  arterial  calciﬁcation,  they
can  avert  its  further  formation  [27].  Therefore,  it  can  be
hypothesized  that  the  increased  osteoprotegerin  concen-
trations  in  patients  with  PAD  may  well  be  an  attempt,  albeit
unsuccessful,  to  impede  the  calciﬁcation  process  in  the
arterial  lesion  [13].  Hyperglycaemia  observed  in  diabetes
is  able  to  modulate  osteoprotegerin  release  by  endothelial
cells  via  a  tumour  necrosis  factor  alpha-dependent  pathway
[28,29].  However,  increased  osteoprotegerin  concentrations
in  patients  with  diabetes  are  not  accompanied  by  a  conco-
mitant  increase  in  its  ligand  (receptor  activator  of  nuclear
factor  kappa-B  ligand  [RANKL])  [28].  An  imbalance  between
osteoprotegerin/RANKL,  resulting  from  an  isolated  increase
in  osteoprotegerin,  but  not  its  ligand,  might  explain  why,
despite  increased  concentrations  in  diabetes,  additional
vasculoprotective  beneﬁts  are  not  seen  [28].
A  direct  link  between  glycaemic  control  and  reduced  PAD
morbidity  is  by  no  means  clear-cut.  The  United  Kingdom
a
t
crospective  Diabetes  Study  (UKPDS)  indicated  that  tight
lycaemic  control  does  not  reduce  the  risk  of  amputations
ue  to  diabetic  foot  [30,31].  Our  ﬁndings  are  in  accord
ith  and  support  these  ﬁndings;  while  patients  with  higher
oncentrations  of  HbA1c had,  at  the  same  time,  higher
steoprotegerin  concentrations,  when  the  glycaemic  con-
rol  factor  was  accounted  for,  the  osteoprotegerin-PAD  link
till  retained  its  signiﬁcance  in  the  multivariable  model.
In  our  study,  patients  with  PAD  were  more  likely  to  have
ypertension  and  also  had  a  worse  lipid  proﬁle.  Previous
tudies  have  conclusively  demonstrated  that  each  of  these
isk  factors  can  contribute  to  the  emergence  and  progression
f  PAD  [22,30,32].  Osteoprotegerin  is,  in  turn,  associated
ith  various  traditional  and  non-traditional  atherosclerosis
isk  factors,  including,  but  not  limited  to,  insulin  resistance,
ypertension,  adiposity,  cigarette  smoking  and  hsCRP  [22].
owever,  we  have  shown  that  if  these  potential  confound-
ng  variables  are  accounted  for,  the  association  between
steoprotegerin  and  PAD  remains  robust.  In  line  with  our
bservations,  Ali  et  al.  also  demonstrated  that  the  associ-
tion  between  osteoprotegerin  and  diminished  ABI  persists
fter  adjustment  for  age,  sex,  diabetes,  hypertension,  lipid
roﬁle,  history  of  cardio-  and  cerebrovascular  disease,  the
edications  used  and  CRP  [22].  Therefore,  it  could  be
rgued  that  the  putative  mechanisms  by  which  osteopro-
egerin  acts  are  not  entirely  dependent  upon  and  are  not
onfounded  by  the  factors  mentioned  above.
4S
A
t
d
g
w
t
a
a
n
t
i
m
r
s
m
s
r
C
D
t
r
O
i
i
F
a
o
m
E
T
D
T
c
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[18  
tudy limitations
 number  of  limitations  in  our  study  deserve  mention.  First,
he  cross-sectional  design  of  the  study  precludes  us  from
rawing  cause  and  effect  inferences  from  the  osteoprote-
erin  and  PAD  relationship,  and  caution  should  be  exercised
hen  interpreting  the  direction  of  the  association.  Second,
he  gold  standard  method  for  diagnosis  of  PAD  is  arterial
ngiography.  However,  angiography  is  invasive,  laborious
nd  costly,  and  it  increases  the  risk  of  contrast-induced
ephropathy  in  diabetes  patients  [5].  It  has  been  suggested
hat  angiography  should  not  be  performed  for  diagnosing  PAD
n  the  ﬁrst  instance,  and  that  other  less  invasive  imaging
odalities  be  used  instead  [31].  Increasing  clinical  expe-
ience  with  colour  Doppler  ultrasonography,  and  its  high
ensitivity  (88%),  speciﬁcity  (95%)  and  accuracy  (93%),  have
ade  this  technique  a  valuable  non-invasive  screening  tool,
paring  low-risk  patients  from  unnecessary  arterial  angiog-
aphy  [33—35].
onclusions
espite  the  aforementioned  limitations,  our  study  con-
ributes  to  the  current  understanding  of  the  multifaceted
ole  of  osteoprotegerin  in  diabetes  and  atherosclerosis.
steoprotegerin  is  associated  with  the  presence  and  sever-
ty  of  lower  extremity  atherosclerosis  in  diabetic  patients,
ndependent  of  traditional  and  non-traditional  risk  factors.
urther  studies  need  to  elucidate  the  exact  molecular  mech-
nisms  involved  and  also  examine  the  possible  clinical  utility
f  osteoprotegerin  as  a  surrogate  diagnostic  and  prognostic
arker  for  PAD  in  patients  with  diabetes.
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